Concepedia

Publication | Open Access

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

DOIFull Paper Access

158

Citations

28

References

2023

Year

Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett, Achim Berthele, J. de Sèze, Michael Levy, Ichiro Nakashima, Celia Oreja‐Guevara, Jacqueline Palace, Friedemann Paul,
Annals of Neurology

Abstract

Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. ANN NEUROL 2023;93:1053-1068.

References

YearCitations

Page 1